Key indicators: single-crystal X-ray study; T = 293 K; mean (C-C) = 0.002 Å; R factor = 0.047; wR factor = 0.156; data-to-parameter ratio = 18.1.
In the title compound, C 25 H 25 NO 3 , the dihydropyran ring adopts a half-chair conformation, whereas the pyrrolidine ring is in a twist conformation. The tolyl group is oriented at an angle of 82.92 (7) with respect to the napthalene ring system. In the crystal structure, molecules are linked into centrosymmetric dimers by C-HÁ Á Á interactions involving the benzene ring of the tolyl group.
Related literature
For the biological activity of pyrrole derivatives, see: Biava et al. (2005) ; Borthwick et al. (2000) ; Caine (1993) ; Carlson (1993) ; Fernandes et al. (2004) ; Jiang et al. (2004) ; Sokoloff et al. (1990) ; Tidey & Miczek (1992) ; Wilner (1985) . For a related structure, see: Gunasekaran et al. (2009) . For ring-puckering parameters, see : Cremer & Pople (1975) .
Experimental
Crystal data 
Data collection
Bruker Kappa-APEXII areadetector diffractometer Absorption correction: multi-scan (Blessing, 1995) T min = 0.980, T max = 0.984 22975 measured reflections 4790 independent reflections 3176 reflections with I > 2(I) R int = 0.028 Table 1 Hydrogen-bond geometry (Å , ).
Symmetry code: (i) Àx; Ày þ 1; Àz þ 1. Cg1 is the centroid of the C16-C21 ring.
Data collection: APEX2 (Bruker, 2004 ); cell refinement: SAINT (Bruker, 2004) ; data reduction: SAINT; program(s) used to solve structure: SHELXS97 (Sheldrick, 2008 ); program(s) used to refine structure: SHELXL97 (Sheldrick, 2008) ; molecular graphics: ORTEP-3 (Farrugia, 1997) ; software used to prepare material for publication: PLATON (Spek, 2009 (Caine, 1993) , aggressiveness (Tidey & Miczek, 1992 ), parkinson's disease (Carlson, 1993) , psychoses, memory disorders (Sokoloff et al., 1990) , anxiety and depression (Wilner, 1985) . Pyrrole derivatives have good in vitro activities against mycobacteria and candidae (Biava et al., 2005) . These derivatives also possess anti-inflammatory (Fernandes et al., 2004) and antiviral (Borthwick et al., 2000) activities. It has also been shown that N-substituted pyrrole derivatives inhibit human immuno deficiency virus type-I (HIV-I) (Jiang et al., 2004) . In view of its medicinal importance, the crystal structure determination of the title compound was undertaken.
The geometric parameters of the title molecule ( Fig. 1 ) agree well with those reported for a similar structure (Gunasekaran et al., 2009) (Table 1) .
Experimental
A mixture of (Z)-methyl 2-((1-formylnaphthalen-2-yloxy)methyl)-3-p-tolylacrylate (20 mmol) and sarcosine (30 mmol) was refluxed in benzene for 20 h and the solvent was removed under reduced pressure. The crude product was subjected to column chromatography to get the pure product. A chloroform and methanol (1:1) solvent mixture was used for the crystallization under slow evaporation method.
Refinement
H atoms were placed in idealized positions and allowed to ride on their parent atoms, with C-H = 0.93, 0.98, 0.97 and 0.96 Å for aromatic, methine, methylene and methyl H respectively, and U iso (H) = 1.5U eq (C) for methyl H and U iso (H) = 1.2U eq (C) for all other H atoms.
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Figures Fig. 1 . The molecular structure of the title compound, with 30% probability displacement ellipsoids. Absorption correction: multi-scan (Blessing, 1995) 
